|
Press Releases |
|
 |
|
Friday, January 10, 2020 |
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
Wednesday, November 20, 2019 |
|
类风湿关节炎治疗市场蓝海潜力巨大 中国抗体公布在研药物SM03类风湿关节炎III期临床试验最新进展 |
中国抗体制药有限公司(「中国抗体」或「公司」,连同其附属公司,统称「集团」;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布其旗舰在研药物SM03类风湿关节炎III期临床试验最新进展。 more info >> |
|
類風濕關節炎治療市場藍海潛力巨大 中國抗體公佈在研藥物SM03類風濕關節炎III期臨床試驗最新進展 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈其旗艦在研藥物SM03類風濕關節炎III期臨床試驗最新進展。 more info >> |
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
Monday, November 11, 2019 |
|
中国抗体(3681.HK):商业化进程未来可期 |
2018年港交所设立新规,允许未盈利公司在香港主板上市,由此揭开了内地生物科技公司赴港上市热潮的序幕。 more info >> |
|
中國抗體(3681.HK):商業化進程未來可期 |
2018年港交所設立新規,允許未盈利公司在香港主板上市,由此揭開了內地生物科技公司赴港上市熱潮的序幕。 more info >> |
|
Wednesday, October 30, 2019 |
|
中国抗体制药宣布于港交所主板上市计划 |
中国抗体制药有限公司(「中国抗体制药」或「公司」连同其附属公司,统称「集团」;股份代号:3681.HK),专门研究、发展、制造及商业化免疫性疾病疗法且主要研制以单克隆抗体为基础的生物药的香港生物制药公司,今天宣布于香港联合交易所有限公司(「联交所」)主板上市计划。 more info >> |
|
中國抗體製藥宣佈於港交所主板上市計劃 |
中國抗體製藥有限公司(「中國抗體製藥」或「公司」連同其附屬公司,統稱「集團」;股份代號:3681.HK),專門研究、發展、製造及商業化免疫性疾病療法且主要研製以單克隆抗體為基礎的生物藥的香港生物製藥公司,今天宣佈於香港聯合交易所有限公司(「聯交所」)主板上市計劃。 more info >> |
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Maximizing Offshore ROI: Unlocking Financial Success in Global Expansion
Feb 16, 2025 19:30 HKT/SGT
|
|
|
Giftify Deploys Enterprise AI Solutions Driving Operational Excellence and Innovation
Feb 16, 2025 18:58 HKT/SGT
|
|
|
Encouraging results expands Kincora Copper and AngloGold Ashanti's First Drilling Program
Feb 14, 2025 23:09 HKT/SGT
|
|
|
B.Duck成功挑戰吉尼斯世界紀錄:83.972M最大的充氣式小黃鴨
Feb 14, 2025 21:20 HKT/SGT
|
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025
Feb 14, 2025 21:00: JST
|
|
|
B.Duck成功挑战吉尼斯世界纪录:83.972M最大的充气式小黄鸭
Feb 14, 2025 20:44 HKT/SGT
|
|
|
China Medical System (867.HK) is Included in the S&P Global Sustainability Yearbook 2025
Feb 14, 2025 20:00 HKT/SGT
|
|
|
Mazda to Strengthen Production and Sales Systems in Thailand
Feb 14, 2025 17:04 JST
|
|
|
Toyota Develops New Fuel Cell System
Feb 14, 2025 15:27 JST
|
|
|
トヨタ、「新型燃料電池システム」を開発
Feb 14, 2025 13:30: JST
|
|
|
康哲藥業(867.HK)入選標普全球《可持續發展年鑒2025》
Feb 14, 2025 12:26 HKT/SGT
|
|
|
康哲药业(867.HK)入选标普全球《可持续发展年鉴2025》
Feb 14, 2025 12:11 HKT/SGT
|
|
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Feb 14, 2025 12:09 JST
|
|
|
アリックスパートナーズ、 「ディスラプション・インデックス2025年版」を発表
Feb 14, 2025 10:00: JST
|
|
|
Graid Technology Announces SupremeRAID SE Support for the NVIDIA GeForce RTX 5000 Series, Expanding High-Performance RAID for Workstations
Feb 14, 2025 00:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|